e-learning
resources
Copenhagen 2005
Sunday 18.09.2005
New perspectives in asthma treatment
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
Indacaterol: preclinical evidence for an improved safety profile vs LABAs
C. A. Lewis, L. Jordan, D. C. Farr, J. Fozard (Horsham, United Kingdom; Basel, Switzerland)
Source:
Annual Congress 2005 - New perspectives in asthma treatment
Session:
New perspectives in asthma treatment
Session type:
Poster Discussion
Number:
1401
Disease area:
Airway diseases
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
C. A. Lewis, L. Jordan, D. C. Farr, J. Fozard (Horsham, United Kingdom; Basel, Switzerland). Indacaterol: preclinical evidence for an improved safety profile vs LABAs. Eur Respir J 2005; 26: Suppl. 49, 1401
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
Late Breaking Abstract - Implications of treatable traits and treatment choices on exacerbation risk in moderate-severe asthma
Management of Severe Asthma in Pediatric Patients by an Interdisciplinary Team in a Public Hospital Setting.
Impact of Dexamethasone on pathogen profile of COVID-19 patients requiring intensive care: a multicentre retrospective study
Related content which might interest you:
Once-daily QVA149 provides the same efficacy as the free combination of its monocomponents indacaterol and glycopyrronium: The BEACON study
Source: Annual Congress 2013 –New clinical trials of asthma and COPD drugs
Year: 2013
Indacaterol once-daily provides superior efficacy to salmeterol: A 12-week trial
Source: Annual Congress 2010 - Regulation of airway hyperresponsiveness and bronchodilators
Year: 2010
Once-daily NVA237 improves lung function in COPD patients: Pooled results of the GLOW1 and GLOW2 studies
Source: Annual Congress 2012 - COPD treatments: efficacy and safety
Year: 2012
Once-daily QVA149 demonstrates superior outcomes in COPD patients previously treated with fixed-dose long-acting beta
2
-agonist/inhaled corticosteroid (LABA/ICS): The ILLUMINATE study
Source: Annual Congress 2013 –Asthma and COPD management: novel clinical findings
Year: 2013
Cardiac safety of indacaterol, a novel once-daily bronchodilator, in asthma
Source: Annual Congress 2008 - Recent advances in the treatment and pathogenesis of asthma
Year: 2008
Indacaterol once-daily provides effective 24-h bronchodilation in COPD patients: a 26-week evaluation
vs
placebo and tiotropium
Source: Annual Congress 2009 - New bronchodilators
Year: 2009
Once-daily NVA237 reduces exacerbations and improves symptoms in COPD patients: A pooled analysis of the GLOW1 and GLOW2 studies
Source: Annual Congress 2012 - Trials in COPD: novel treatments and insights
Year: 2012
Aclidinium bromide, a novel long-acting anticholinergic drug, has a good preclinical cardiovascular safety profile
Source: Annual Congress 2008 - Novel experimental approaches to understanding asthma and COPD
Year: 2008
Cardiac safety of indacaterol, a novel once-daily bronchodilator, in COPD
Source: Annual Congress 2008 - Pathogenesis and treatment of asthma and COPD
Year: 2008
Comparison of efficacy and safety of twice-daily Glycopyrronium/Formoterol combination with once-daily Glycopyrronium in patients with moderate to severe COPD
Source: International Congress 2019 – COPD clinical trials: inhaled and oral therapies
Year: 2019
Long-acting β-agonists: a review of formoterol safety data from asthma clinical trials
Source: Eur Respir J 2009; 33: 21-32
Year: 2009
Safety of long-acting β-agonist (LABA) withdrawal in patients in two clinical asthma trials
Source: Annual Congress 2012 - Different ways to phenotype asthma
Year: 2012
Efficacy and safety of transdermal tulobuterol (LABA) on asthma patients
Source: Annual Congress 2007 - New treatments for asthma
Year: 2007
Once-daily QVA149 provides clinically meaningful improvements in lung function and clinical outcomes
Source: Annual Congress 2013 –Asthma and COPD drugs: efficacy, safety and pharmacoeconomics
Year: 2013
Triple therapy versus dual bronchodilation and long-acting ß-agonists/inhaled corticosteroids in COPD: accumulating evidence from network meta-analyses
Source: International Congress 2019 – Therapeutic breakthrough Year in review
Year: 2019
Mometasone furoate/formoterol (MF/F) combination for the treatment of asthma: safety and tolerability findings from a clinical trial in severe asthma patients
Source: Annual Congress 2009 - Towards improving asthma control
Year: 2009
Formoterol as relief medication in asthma: a worldwide safety and effectiveness trial
Source: Eur Respir J 2003; 22: 787-794
Year: 2003
Comparative efficacy of umeclidinium/vilanterol versus LABA/LAMA therapies in COPD: A network meta-analysis
Source: International Congress 2016 – Pharmacological treatment of COPD: focus on LABA/LAMA combinations
Year: 2016
AMPLIFY: efficacy of aclidinium vs tiotropium in COPD
Source: International Congress 2018 – COPD management
Year: 2018
Efficacy and safety profile of doxofylline compared to theophylline in asthma: a meta-analysis
Source: International Congress 2019 – Asthma: outcomes of clinical trials and cohorts
Year: 2019
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept